NOVAVAX, INC. financials

NVAX CIK 0001000694

Source: EDGAR filings · Built 2026-06-02T03:41:59Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -260.27M -104.31M -795.08M -598.59M 137.55M -193.23M
EBITDA 480.80M -200.93M -525.51M -615.74M -1.67B -412.42M
Working Capital 518.33M -25.47M -491.25M -756.55M -235.20M 668.53M
Net Debt 37.41M -266.76M -226.81M -661.72M -860.49M 74.43M
Gross Margin 93.50% 70.28% 65.05% 54.46% 100.00% 100.00%
Operating Margin 40.30% -36.49% -57.59% -32.53% -147.13% -87.62%
Net Margin 39.19% -27.49% -55.41% -33.20% -152.12% -87.94%
Return on Equity (ROE) -344.65% 30.06% 76.03% 103.76% 495.84% -66.69%
Return on Assets (ROA) 37.42% -12.02% -30.32% -29.13% -67.67% -26.43%
Current Ratio 2.13× 0.98× 0.70× 0.69× 0.90× 2.15×
Debt-to-Equity -2.18× -0.42× -0.48× -1.06× -1.86× 1.00×
Effective Tax Rate 0.42% -6.16% -0.37% -0.66% -1.70% 0.00%
Cash Conversion Ratio -0.56× 0.47× 1.31× 0.63× -0.19× 0.10×
Accruals Ratio 0.58× -0.06× 0.09× -0.11× -0.80× -0.24×
SBC % of Revenue 3.21% 7.06% 8.68% 6.57% 16.02% 26.92%
CapEx Coverage -15.65× -5.12× -8.80× -2.28× 1.74× -0.28×
Free Cash Flow Per Share $-1.50 $-0.69 $-7.89 $-7.66 $1.85 $-3.36

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 2.60×
P/FCF 77.39×
FCF Yield 1.29%
EV / EBITDA 2.35×
P/S 0.97× 1.89× 0.68× 0.45× 9.47× 16.64×
P/B 12.61×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 1.12B 682.16M 983.71M 1.98B
Revenues 1.12B 682.16M 983.71M 1.98B 1.15B 475.60M
Cost of Revenue 73.04M 202.74M 343.77M 902.64M 0 0
Research and Development Expense 342.32M 391.17M 737.50M 1.24B 2.53B 747.03M
Selling, General and Administrative Expense 157.48M 337.19M 468.95M 488.69M
Operating Income (Loss) 452.80M -248.93M -566.51M -644.74M -1.69B -416.72M
Income Tax Expense (Benefit) 1.86M 10.88M 2.03M 4.29M 29.21M 0
Net Income (Loss) Attributable to Parent 440.30M -187.50M -545.06M -657.94M -1.74B -418.26M
Earnings Per Share, Basic $2.72 $-1.23 $-5.41 $-8.42 $-23.44 $-7.27
Weighted Average Number of Shares Outstanding, Basic 161.99M 152.19M 100.77M 78.18M 74.40M 57.55M
Earnings Per Share, Diluted $2.58 $-1.23 $-5.41 $-8.42 $-23.44 $-7.27
Weighted Average Number of Shares Outstanding, Diluted 173.10M 152.19M 100.77M 78.18M 74.40M 57.55M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 240.63M 530.23M 568.50M 1.34B 1.52B 553.40M
Assets, Current 978.28M 1.13B 1.14B 1.70B 2.16B 1.25B
Assets 1.18B 1.56B 1.80B 2.26B 2.58B 1.58B
Long-term Debt 244.21M
Liabilities, Current 459.95M 1.15B 1.64B 2.46B 2.39B 579.67M
Liabilities 1.30B 2.18B 2.51B 2.89B 2.93B 955.27M
Stockholders' Equity Attributable to Parent -127.75M -623.84M -716.93M -634.08M -351.67M 627.21M
Common Stock, Shares, Outstanding 162.58M 160.42M 139.51M 86.04M 75.84M 70.95M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -244.63M -87.26M -713.97M -415.94M 322.95M -42.54M
Net Cash Provided by (Used in) Investing Activities -78.27M -204.04M -58.81M -92.98M 100.15M -377.78M
Net Cash Provided by (Used in) Financing Activities 27.74M 260.58M 4.47M 324.99M 461.71M 984.76M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (NVAX CIK 0001000694), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DNLI

Denali Therapeutics Inc.

NAVN

NAVAN, INC.

VITL

Vital Farms, Inc.